Cardiff Oncology, Inc. (CRDF) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	508.0K	593.0K	683.0K	488.0K	386.0K
Cost of Revenue	—	—	—	—	—
Gross Profit	508.0K	593.0K	683.0K	488.0K	386.0K
Operating Expenses
R&D Expense	26.0M	35.3M	36.9M	32.9M	27.1M
SG&A Expense	16.8M	14.2M	12.5M	13.0M	13.2M
General & Admin Expense	16.8M	14.2M	12.5M	13.0M	13.2M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	42.8M	49.6M	49.3M	45.9M	40.3M
Cost and Expenses	42.8M	49.6M	49.3M	45.9M	40.3M
Operating Income (EBIT)	(42.3M)	(49.0M)	(48.7M)	(45.4M)	(39.9M)
Non-Operating
Interest Income	2.2M	3.1M	3.3M	4.1M	1.6M
Interest Expense	—	—	—	—	—
Net Interest Income	2.2M	3.1M	3.3M	4.1M	1.6M
Other Non-Op Income/Expense	2.2M	3.1M	3.2M	4.0M	1.2M
Non-Operating Income (excl Interest)	(2.2M)	(3.1M)	(3.2M)	(4.0M)	(1.2M)
EBT (Pre-Tax Income)	(40.1M)	(45.9M)	(45.4M)	(41.4M)	(38.7M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(40.1M)	(45.9M)	(45.4M)	(41.4M)	(38.7M)
Earnings from Cont. Ops	(40.1M)	(45.9M)	(45.4M)	(41.4M)	(38.7M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(40.1M)	(45.9M)	(45.5M)	(41.5M)	(38.7M)
Per Share
Basic EPS	($0.60)	($0.69)	($0.95)	($0.93)	($0.89)
Diluted EPS	($0.60)	($0.69)	($0.95)	($0.93)	($0.89)
Revenue Per Share	$0.01	$0.01	$0.01	$0.01	$0.01
Shares
Basic Shares Outstanding	68.4M	66.8M	47.6M	44.7M	43.6M
Diluted Shares Outstanding	68.4M	66.8M	47.6M	44.7M	43.6M
Profitability Metrics
EBITDA	(38.9M)	(44.9M)	(45.0M)	(41.0M)	(38.5M)
D&A	1.1M	904.0K	404.0K	398.0K	236.0K
EBIT	(40.1M)	(45.9M)	(45.4M)	(41.4M)	(38.7M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026